Sign In
Buy ADIL
$2.71
+0.110 (+4.23%)
At Close: Jun 22, 2026
Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Decreases By 31.2%
01:19am, Monday, 29'th Dec 2025
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL - Get Free Report) was the target of a significant decrease in short interest in December. As of December 15th, there was short interest totaling 407,422 shar
Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
08:30am, Friday, 14'th Nov 2025
GLEN ALLEN, Va. , Nov. 14, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies fo
Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Drops By 59.6%
01:48am, Friday, 31'st Oct 2025
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL - Get Free Report) was the recipient of a significant decrease in short interest in the month of October. As of October 15th, there was short interest totalin
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Sees Large Decline in Short Interest
01:58am, Thursday, 30'th Oct 2025
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL - Get Free Report) was the recipient of a large decline in short interest in the month of October. As of October 15th, there was short interest totaling 448,1
Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show
09:00am, Friday, 17'th Oct 2025
GLEN ALLEN, Va., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing thera
Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution
08:30am, Thursday, 09'th Oct 2025
Partnership has successfully completed analytical validation of a cheek swab collection solution for testing and identifying patients with the genotypes important for AD04 development Partnership has
Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04
08:00am, Tuesday, 16'th Sep 2025
FDA Minutes Reflect Constructive Dialogue and Successful Meeting Outcome with Alignment on Upcoming Phase 3 Clinical Trial Design for AD04 In Alcohol Use Disorder FDA Minutes Reflect Constructive Dial
Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule
08:30am, Wednesday, 03'rd Sep 2025
GLEN ALLEN, Va., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing ther
All You Need to Know About Adial Pharmaceuticals (ADIL) Rating Upgrade to Buy
01:01pm, Monday, 01'st Sep 2025
Adial Pharmaceuticals (ADIL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
08:30am, Thursday, 14'th Aug 2025
GLEN ALLEN, Va., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing thera
Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting
08:00am, Wednesday, 06'th Aug 2025
Meeting Completion Marks Major Step Toward Phase 3 AD04 Trial Launch Strategic Partnership Discussions Expected Following the Positive FDA Meeting GLEN ALLEN, Va., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Ad
Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders' Equity Listing Requirement
08:30am, Wednesday, 16'th Jul 2025
GLEN ALLEN, Va., July 16, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing thera
Adial Pharmaceuticals (ADIL) Upgraded to Strong Buy: Here's Why
01:01pm, Thursday, 10'th Jul 2025
Adial Pharmaceuticals (ADIL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045
08:30am, Wednesday, 09'th Jul 2025
GLEN ALLEN, Va., July 09, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing thera
Scope of Agreement with Cambrex to Provide Ondansetron HCL Drug Substance Under FDA Approved Drug Master File Scope Of Agreement With Thermo Fisher to Provide Manufacturing Services Including Demonstr
